ART Proximal Restorations Using Encapsulated GIC - RCT

Objectives: The aim of this randomized clinical trial was to evaluate the occlusal-proximal restorations survival rate performed by ART, comparing two encapsulated glass ionomer cements: Equia Forte (GC Corp) and Riva Self Cure (SDI).
Methods: The register in Clinical Trials is NCT02730000 and Ethical Board approval is 1.608.416. One hundred and fifty-one (151) patients from 4 to 8 years old presenting occlusal-proximal caries lesions in primary molars were selected in the city of Tiete / SP. Patients were randomized into two groups and treated in accordance with the original ART, in a school setting. The restorations were evaluated after 1 month by a trained evaluator (Kappa = 0.97). To analyze the results, it was used the Kaplan Meyer test, log rank, and logistic regression to compare outcome and associated variables. The significance level was set at 5%.
Results: After 1-month follow-up, the overall survival of the restorations was 85.43%. Survival rates for group Equia and Riva, were 88.2% and 82.7%, respectively. Statistical analysis showed no significant difference between the materials (OR = 0.64, CI 0.25 to 1.60; p = 0.341). The other variables: operator, caries experience, restored surface, volume of the cavity, plaque index, gingival general health and the treated tooth, also showed no significant differences.
Conclusions: There is no difference in clinical success among Riva and Equia after 1-month follow-up in approximal cavities in primary teeth.